The Center for Research in Inflammatory Diseases (CRID) was created with the aim of producing integrative and translational scientific research to identify and validate new biological pathways involved in the induction and resolution of inflammation. To this end, it counts on the experience of researchers from various fields of Biomedical Sciences linked to basic research (genetics, molecular and cell biology, immunology, pharmacology, and pathology) and clinical research (rheumatology, immunology, infectology, and dermatology), in addition to researchers in the area of bioinformatics.
Inflammatory diseases constitute a complex and heterogeneous group of diseases that affect more than 10% of the world population. The treatment alternatives currently available are limited and, in some cases, ineffective, considering that information on the underlying mechanisms of the inflammatory process and the pathophysiology of inflammatory diseases is still lacking.
The specific objective of the Center is to advance knowledge about inflammatory diseases (infectious, autoimmune, and related to the cardiovascular system) to recognize and understand the molecular, immunological, pathological, and pharmacological mechanisms involved; identify new biological targets for the development of pharmacological therapeutic tools; search for possible diagnostic markers and prognostic indications, and apply new knowledge to design and synthesize molecules aimed at treating inflammatory diseases.
A team affiliated with a FAPESP-supported research center showed in mice that molecules capable of preventing the peptide C5a from binding to its cellular receptor helped prevent lung damage and other complications typical of severe COVID-19.
A study conducted at the University of São Paulo and reported in PNAS explains hyperglycemia in hospitalized patients and shows how SARS-CoV-2 causes symptoms similar to those of diabetes.
Leishmania alters the structure of the human protein that would normally induce the death of infected cells and weakens the inflammatory response. Reported in Nature Communications, the discovery could serve as a basis for better treatment.
Scientists who analyzed the combined use of two drugs – paclitaxel and immune checkpoint inhibitors – made discoveries that could pave the way for future research to combat the pain caused by other diseases.
Neuropathic pain is chronic and caused by injury to the nervous system, affecting between 3% and 15% of the population. The only treatment options currently available are drugs originally developed for other conditions, such as epilepsy or depression.
A study conducted at the University of São Paulo shows that flaws in the metabolization of ATP, one of the main sources of cellular energy, can lead to dysregulation of the immune system and a dangerously exacerbated inflammatory response to infection by the novel coronavirus.
Bioinformatics, engineering and other disciplines driven by advances in computing were discussed by participants in an online seminar hosted by the São Paulo State Academy of Sciences to present the fifth chapter of FAPESP 60 Anos: A Ciência no Desenvolvimento Nacional.
Researchers at the University of São Paulo tested the anthelmintic niclosamide on mice and human blood cells. In addition to exhibiting antiviral action, the drug deactivated the cellular mechanism that triggers a cytokine storm. A novel formulation is required for the active principle to reach the lungs and treat severe COVID-19 in humans.
Brazilian researchers have developed a tool that encodes patient identification data as DNA sequences and integrates databases with millions of records despite misspellings and omissions. The platform is fast and accurate and can be used for epidemiological analysis and public policy formulation.